Cargando…

The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network

BACKGROUND: There is a high risk of Plasmodium vivax parasitaemia following treatment of falciparum malaria. Our study aimed to quantify this risk and the associated determinants using an individual patient data meta-analysis in order to identify populations in which a policy of universal radical cu...

Descripción completa

Detalles Bibliográficos
Autores principales: Hossain, Mohammad S., Commons, Robert J., Douglas, Nicholas M., Thriemer, Kamala, Alemayehu, Bereket H., Amaratunga, Chanaki, Anvikar, Anupkumar R., Ashley, Elizabeth A., Asih, Puji B. S., Carrara, Verena I., Lon, Chanthap, D’Alessandro, Umberto, Davis, Timothy M. E., Dondorp, Arjen M., Edstein, Michael D., Fairhurst, Rick M., Ferreira, Marcelo U., Hwang, Jimee, Janssens, Bart, Karunajeewa, Harin, Kiechel, Jean R., Ladeia-Andrade, Simone, Laman, Moses, Mayxay, Mayfong, McGready, Rose, Moore, Brioni R., Mueller, Ivo, Newton, Paul N., Thuy-Nhien, Nguyen T., Noedl, Harald, Nosten, Francois, Phyo, Aung P., Poespoprodjo, Jeanne R., Saunders, David L., Smithuis, Frank, Spring, Michele D., Stepniewska, Kasia, Suon, Seila, Suputtamongkol, Yupin, Syafruddin, Din, Tran, Hien T., Valecha, Neena, Van Herp, Michel, Van Vugt, Michele, White, Nicholas J., Guerin, Philippe J., Simpson, Julie A., Price, Ric N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676739/
https://www.ncbi.nlm.nih.gov/pubmed/33211712
http://dx.doi.org/10.1371/journal.pmed.1003393
_version_ 1783611834873413632
author Hossain, Mohammad S.
Commons, Robert J.
Douglas, Nicholas M.
Thriemer, Kamala
Alemayehu, Bereket H.
Amaratunga, Chanaki
Anvikar, Anupkumar R.
Ashley, Elizabeth A.
Asih, Puji B. S.
Carrara, Verena I.
Lon, Chanthap
D’Alessandro, Umberto
Davis, Timothy M. E.
Dondorp, Arjen M.
Edstein, Michael D.
Fairhurst, Rick M.
Ferreira, Marcelo U.
Hwang, Jimee
Janssens, Bart
Karunajeewa, Harin
Kiechel, Jean R.
Ladeia-Andrade, Simone
Laman, Moses
Mayxay, Mayfong
McGready, Rose
Moore, Brioni R.
Mueller, Ivo
Newton, Paul N.
Thuy-Nhien, Nguyen T.
Noedl, Harald
Nosten, Francois
Phyo, Aung P.
Poespoprodjo, Jeanne R.
Saunders, David L.
Smithuis, Frank
Spring, Michele D.
Stepniewska, Kasia
Suon, Seila
Suputtamongkol, Yupin
Syafruddin, Din
Tran, Hien T.
Valecha, Neena
Van Herp, Michel
Van Vugt, Michele
White, Nicholas J.
Guerin, Philippe J.
Simpson, Julie A.
Price, Ric N.
author_facet Hossain, Mohammad S.
Commons, Robert J.
Douglas, Nicholas M.
Thriemer, Kamala
Alemayehu, Bereket H.
Amaratunga, Chanaki
Anvikar, Anupkumar R.
Ashley, Elizabeth A.
Asih, Puji B. S.
Carrara, Verena I.
Lon, Chanthap
D’Alessandro, Umberto
Davis, Timothy M. E.
Dondorp, Arjen M.
Edstein, Michael D.
Fairhurst, Rick M.
Ferreira, Marcelo U.
Hwang, Jimee
Janssens, Bart
Karunajeewa, Harin
Kiechel, Jean R.
Ladeia-Andrade, Simone
Laman, Moses
Mayxay, Mayfong
McGready, Rose
Moore, Brioni R.
Mueller, Ivo
Newton, Paul N.
Thuy-Nhien, Nguyen T.
Noedl, Harald
Nosten, Francois
Phyo, Aung P.
Poespoprodjo, Jeanne R.
Saunders, David L.
Smithuis, Frank
Spring, Michele D.
Stepniewska, Kasia
Suon, Seila
Suputtamongkol, Yupin
Syafruddin, Din
Tran, Hien T.
Valecha, Neena
Van Herp, Michel
Van Vugt, Michele
White, Nicholas J.
Guerin, Philippe J.
Simpson, Julie A.
Price, Ric N.
author_sort Hossain, Mohammad S.
collection PubMed
description BACKGROUND: There is a high risk of Plasmodium vivax parasitaemia following treatment of falciparum malaria. Our study aimed to quantify this risk and the associated determinants using an individual patient data meta-analysis in order to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy (ACT) with a hypnozoitocidal antimalarial drug, would be beneficial. METHODS AND FINDINGS: A systematic review of Medline, Embase, Web of Science, and the Cochrane Database of Systematic Reviews identified efficacy studies of uncomplicated falciparum malaria treated with ACT that were undertaken in regions coendemic for P. vivax between 1 January 1960 and 5 January 2018. Data from eligible studies were pooled using standardised methodology. The risk of P. vivax parasitaemia at days 42 and 63 and associated risk factors were investigated by multivariable Cox regression analyses. Study quality was assessed using a tool developed by the Joanna Briggs Institute. The study was registered in the International Prospective Register of Systematic Reviews (PROSPERO: CRD42018097400). In total, 42 studies enrolling 15,341 patients were included in the analysis, including 30 randomised controlled trials and 12 cohort studies. Overall, 14,146 (92.2%) patients had P. falciparum monoinfection and 1,195 (7.8%) mixed infection with P. falciparum and P. vivax. The median age was 17.0 years (interquartile range [IQR] = 9.0–29.0 years; range = 0–80 years), with 1,584 (10.3%) patients younger than 5 years. 2,711 (17.7%) patients were treated with artemether-lumefantrine (AL, 13 studies), 651 (4.2%) with artesunate-amodiaquine (AA, 6 studies), 7,340 (47.8%) with artesunate-mefloquine (AM, 25 studies), and 4,639 (30.2%) with dihydroartemisinin-piperaquine (DP, 16 studies). 14,537 patients (94.8%) were enrolled from the Asia-Pacific region, 684 (4.5%) from the Americas, and 120 (0.8%) from Africa. At day 42, the cumulative risk of vivax parasitaemia following treatment of P. falciparum was 31.1% (95% CI 28.9–33.4) after AL, 14.1% (95% CI 10.8–18.3) after AA, 7.4% (95% CI 6.7–8.1) after AM, and 4.5% (95% CI 3.9–5.3) after DP. By day 63, the risks had risen to 39.9% (95% CI 36.6–43.3), 42.4% (95% CI 34.7–51.2), 22.8% (95% CI 21.2–24.4), and 12.8% (95% CI 11.4–14.5), respectively. In multivariable analyses, the highest rate of P. vivax parasitaemia over 42 days of follow-up was in patients residing in areas of short relapse periodicity (adjusted hazard ratio [AHR] = 6.2, 95% CI 2.0–19.5; p = 0.002); patients treated with AL (AHR = 6.2, 95% CI 4.6–8.5; p < 0.001), AA (AHR = 2.3, 95% CI 1.4–3.7; p = 0.001), or AM (AHR = 1.4, 95% CI 1.0–1.9; p = 0.028) compared with DP; and patients who did not clear their initial parasitaemia within 2 days (AHR = 1.8, 95% CI 1.4–2.3; p < 0.001). The analysis was limited by heterogeneity between study populations and lack of data from very low transmission settings. Study quality was high. CONCLUSIONS: In this meta-analysis, we found a high risk of P. vivax parasitaemia after treatment of P. falciparum malaria that varied significantly between studies. These P. vivax infections are likely attributable to relapses that could be prevented with radical cure including a hypnozoitocidal agent; however, the benefits of such a novel strategy will vary considerably between geographical areas.
format Online
Article
Text
id pubmed-7676739
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-76767392020-12-02 The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network Hossain, Mohammad S. Commons, Robert J. Douglas, Nicholas M. Thriemer, Kamala Alemayehu, Bereket H. Amaratunga, Chanaki Anvikar, Anupkumar R. Ashley, Elizabeth A. Asih, Puji B. S. Carrara, Verena I. Lon, Chanthap D’Alessandro, Umberto Davis, Timothy M. E. Dondorp, Arjen M. Edstein, Michael D. Fairhurst, Rick M. Ferreira, Marcelo U. Hwang, Jimee Janssens, Bart Karunajeewa, Harin Kiechel, Jean R. Ladeia-Andrade, Simone Laman, Moses Mayxay, Mayfong McGready, Rose Moore, Brioni R. Mueller, Ivo Newton, Paul N. Thuy-Nhien, Nguyen T. Noedl, Harald Nosten, Francois Phyo, Aung P. Poespoprodjo, Jeanne R. Saunders, David L. Smithuis, Frank Spring, Michele D. Stepniewska, Kasia Suon, Seila Suputtamongkol, Yupin Syafruddin, Din Tran, Hien T. Valecha, Neena Van Herp, Michel Van Vugt, Michele White, Nicholas J. Guerin, Philippe J. Simpson, Julie A. Price, Ric N. PLoS Med Research Article BACKGROUND: There is a high risk of Plasmodium vivax parasitaemia following treatment of falciparum malaria. Our study aimed to quantify this risk and the associated determinants using an individual patient data meta-analysis in order to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy (ACT) with a hypnozoitocidal antimalarial drug, would be beneficial. METHODS AND FINDINGS: A systematic review of Medline, Embase, Web of Science, and the Cochrane Database of Systematic Reviews identified efficacy studies of uncomplicated falciparum malaria treated with ACT that were undertaken in regions coendemic for P. vivax between 1 January 1960 and 5 January 2018. Data from eligible studies were pooled using standardised methodology. The risk of P. vivax parasitaemia at days 42 and 63 and associated risk factors were investigated by multivariable Cox regression analyses. Study quality was assessed using a tool developed by the Joanna Briggs Institute. The study was registered in the International Prospective Register of Systematic Reviews (PROSPERO: CRD42018097400). In total, 42 studies enrolling 15,341 patients were included in the analysis, including 30 randomised controlled trials and 12 cohort studies. Overall, 14,146 (92.2%) patients had P. falciparum monoinfection and 1,195 (7.8%) mixed infection with P. falciparum and P. vivax. The median age was 17.0 years (interquartile range [IQR] = 9.0–29.0 years; range = 0–80 years), with 1,584 (10.3%) patients younger than 5 years. 2,711 (17.7%) patients were treated with artemether-lumefantrine (AL, 13 studies), 651 (4.2%) with artesunate-amodiaquine (AA, 6 studies), 7,340 (47.8%) with artesunate-mefloquine (AM, 25 studies), and 4,639 (30.2%) with dihydroartemisinin-piperaquine (DP, 16 studies). 14,537 patients (94.8%) were enrolled from the Asia-Pacific region, 684 (4.5%) from the Americas, and 120 (0.8%) from Africa. At day 42, the cumulative risk of vivax parasitaemia following treatment of P. falciparum was 31.1% (95% CI 28.9–33.4) after AL, 14.1% (95% CI 10.8–18.3) after AA, 7.4% (95% CI 6.7–8.1) after AM, and 4.5% (95% CI 3.9–5.3) after DP. By day 63, the risks had risen to 39.9% (95% CI 36.6–43.3), 42.4% (95% CI 34.7–51.2), 22.8% (95% CI 21.2–24.4), and 12.8% (95% CI 11.4–14.5), respectively. In multivariable analyses, the highest rate of P. vivax parasitaemia over 42 days of follow-up was in patients residing in areas of short relapse periodicity (adjusted hazard ratio [AHR] = 6.2, 95% CI 2.0–19.5; p = 0.002); patients treated with AL (AHR = 6.2, 95% CI 4.6–8.5; p < 0.001), AA (AHR = 2.3, 95% CI 1.4–3.7; p = 0.001), or AM (AHR = 1.4, 95% CI 1.0–1.9; p = 0.028) compared with DP; and patients who did not clear their initial parasitaemia within 2 days (AHR = 1.8, 95% CI 1.4–2.3; p < 0.001). The analysis was limited by heterogeneity between study populations and lack of data from very low transmission settings. Study quality was high. CONCLUSIONS: In this meta-analysis, we found a high risk of P. vivax parasitaemia after treatment of P. falciparum malaria that varied significantly between studies. These P. vivax infections are likely attributable to relapses that could be prevented with radical cure including a hypnozoitocidal agent; however, the benefits of such a novel strategy will vary considerably between geographical areas. Public Library of Science 2020-11-19 /pmc/articles/PMC7676739/ /pubmed/33211712 http://dx.doi.org/10.1371/journal.pmed.1003393 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication.
spellingShingle Research Article
Hossain, Mohammad S.
Commons, Robert J.
Douglas, Nicholas M.
Thriemer, Kamala
Alemayehu, Bereket H.
Amaratunga, Chanaki
Anvikar, Anupkumar R.
Ashley, Elizabeth A.
Asih, Puji B. S.
Carrara, Verena I.
Lon, Chanthap
D’Alessandro, Umberto
Davis, Timothy M. E.
Dondorp, Arjen M.
Edstein, Michael D.
Fairhurst, Rick M.
Ferreira, Marcelo U.
Hwang, Jimee
Janssens, Bart
Karunajeewa, Harin
Kiechel, Jean R.
Ladeia-Andrade, Simone
Laman, Moses
Mayxay, Mayfong
McGready, Rose
Moore, Brioni R.
Mueller, Ivo
Newton, Paul N.
Thuy-Nhien, Nguyen T.
Noedl, Harald
Nosten, Francois
Phyo, Aung P.
Poespoprodjo, Jeanne R.
Saunders, David L.
Smithuis, Frank
Spring, Michele D.
Stepniewska, Kasia
Suon, Seila
Suputtamongkol, Yupin
Syafruddin, Din
Tran, Hien T.
Valecha, Neena
Van Herp, Michel
Van Vugt, Michele
White, Nicholas J.
Guerin, Philippe J.
Simpson, Julie A.
Price, Ric N.
The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network
title The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network
title_full The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network
title_fullStr The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network
title_full_unstemmed The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network
title_short The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network
title_sort risk of plasmodium vivax parasitaemia after p. falciparum malaria: an individual patient data meta-analysis from the worldwide antimalarial resistance network
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676739/
https://www.ncbi.nlm.nih.gov/pubmed/33211712
http://dx.doi.org/10.1371/journal.pmed.1003393
work_keys_str_mv AT hossainmohammads theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT commonsrobertj theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT douglasnicholasm theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT thriemerkamala theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT alemayehubereketh theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT amaratungachanaki theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT anvikaranupkumarr theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT ashleyelizabetha theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT asihpujibs theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT carraraverenai theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT lonchanthap theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT dalessandroumberto theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT davistimothyme theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT dondorparjenm theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT edsteinmichaeld theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT fairhurstrickm theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT ferreiramarcelou theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT hwangjimee theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT janssensbart theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT karunajeewaharin theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT kiecheljeanr theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT ladeiaandradesimone theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT lamanmoses theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT mayxaymayfong theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT mcgreadyrose theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT moorebrionir theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT muellerivo theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT newtonpauln theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT thuynhiennguyent theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT noedlharald theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT nostenfrancois theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT phyoaungp theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT poespoprodjojeanner theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT saundersdavidl theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT smithuisfrank theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT springmicheled theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT stepniewskakasia theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT suonseila theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT suputtamongkolyupin theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT syafruddindin theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT tranhient theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT valechaneena theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT vanherpmichel theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT vanvugtmichele theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT whitenicholasj theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT guerinphilippej theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT simpsonjuliea theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT pricericn theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT hossainmohammads riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT commonsrobertj riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT douglasnicholasm riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT thriemerkamala riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT alemayehubereketh riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT amaratungachanaki riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT anvikaranupkumarr riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT ashleyelizabetha riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT asihpujibs riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT carraraverenai riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT lonchanthap riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT dalessandroumberto riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT davistimothyme riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT dondorparjenm riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT edsteinmichaeld riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT fairhurstrickm riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT ferreiramarcelou riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT hwangjimee riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT janssensbart riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT karunajeewaharin riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT kiecheljeanr riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT ladeiaandradesimone riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT lamanmoses riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT mayxaymayfong riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT mcgreadyrose riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT moorebrionir riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT muellerivo riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT newtonpauln riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT thuynhiennguyent riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT noedlharald riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT nostenfrancois riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT phyoaungp riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT poespoprodjojeanner riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT saundersdavidl riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT smithuisfrank riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT springmicheled riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT stepniewskakasia riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT suonseila riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT suputtamongkolyupin riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT syafruddindin riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT tranhient riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT valechaneena riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT vanherpmichel riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT vanvugtmichele riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT whitenicholasj riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT guerinphilippej riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT simpsonjuliea riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
AT pricericn riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork